The road to success is paved with dolutegravir: Dolutegravir treatment success among in children and adolescents living with HIV (CALHIV) at the Baylor Tanzania Centres of Excellence.

Bacha, J.; Mayalla, B.; Chodota, M., et. al.,

dc.contributor.author	Bacha, J.
dc.contributor.author	Mayalla, B.
dc.contributor.author	Chodota, M., et. al.,
dc.date.accessioned	2023-05-26T06:22:09Z
dc.date.available	2023-05-26T06:22:09Z
dc.date.issued	2021
dc.identifier.uri	http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/3377
dc.description.abstract	Efficacy and safety data of novel antiretrovirals, such as dolutegravir (DTG), in children and adolescents, often lags behind adult data, and can lead to hesitation and slow uptake by HIV clinicians. Beginning in 2019, the Baylor Tanzania programme began an enthusiastic rollout of DTG among CALHIV. We describe outcomes and safety data of this DTG rollout among CALHIV enrolled at the Baylor Tanzania clinics in Mbeya and Mwanza, Tanzania. Methods: Retrospective chart review was conducted to describe outcomes and safety data of CALHIV who received DTG as part of their ART at the Baylor College of Medicine Children's Foundation -Tanzania Centres of...	en_US
dc.publisher	Journal of the International AIDS Society.	en_US
dc.subject	HIV	en_US
dc.subject	Dolutegravir	en_US
dc.subject	TANZANIA CENTRES OF EXCELLENCY	en_US
dc.title	The road to success is paved with dolutegravir: Dolutegravir treatment success among in children and adolescents living with HIV (CALHIV) at the Baylor Tanzania Centres of Excellence.	en_US
dc.type	Article	en_US